FluGen adds $2 million

Madison-based FluGen has added $2 million to an investment round originally announced in August 2015 that has raised a total of $11.4 million so far.

FluGen is producing RedeeFlu, a single replication live influenza virus vaccine that is distributed into the nose.

Venture Investors, the Wisconsin Alumni Research Foundation, and the state of Wisconsin Investment Board were contributors.